Stem cell transplant with gentler immune therapy
Part of Blood & lymphatic, Cancer clinical trials.
This trial offers a stem cell transplant from a half-matched (haploidentical) donor for children. It uses an early medicine to calm the immune system and a lower dose of a drug to prevent rejection and graft-versus-host disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child or teen at Samsung Medical Center needing a stem cell transplant.
- The donor is a half-matched family member (like a parent or sibling).
- You are getting a special preparative regimen with early anti-thymocyte globulin (ATG) and low-dose post-transplant cyclophosphamide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
This trial tests a combination of two drugs (PTCy and ATG) to prevent graft-versus-host disease after a stem cell transplant from a matched donor. It is for adults with certain blood cancers who are between 18 and 60 and have a suitable donor.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests a stem cell transplant option for children or young adults with severe aplastic anemia that did not respond to prior immune-suppressing treatment. It uses a “half-matched” donor and gives post-transplant cyclophosphamide to help the donor cells work and reduce certain immune reactions.
This trial studies a type of stem cell transplant (bone marrow transplant) that uses a donor who is only half-matched to the patient, often a parent or sibling. It is for children and young adults with certain blood diseases, including sickle cell disease, thalassemia, bone marrow failure, and immune disorders. The transplant aims to replace the diseased blood-forming cells with healthy ones from the donor.
This trial provides a special type of stem cell transplant for people under 22 years old who don't have a fully matched sibling donor. It uses a method to remove certain cells from the donor's stem cells to reduce the risk of graft-versus-host disease, where the donor cells attack the patient's body.
Hear when a new Haploidentical Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.